GMMG multiple myeloma long-term follow-up registry

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The GMMG registry is a national, non-interventional database that combines retrospective and prospective clinical data from patients enrolled in GMMG-led therapy trials across Germany. It links trial databases with ongoing follow-up information to capture outcomes such as overall survival, progression-free survival, cause of death and therapy-free intervals after first relapse. Data are pseudonymized and entered into an electronic case report form with follow-up visits every six months until first progression and annually thereafter. The registry was activated in December 2022 and currently includes data from 35 participating GMMG centers, with no fixed sample size limit.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Previous participation in a a therapy study of the GMMG study group

Exclusion Criteria:

* patients with organ amyloidosis at time of diagnosis

Where it's running

• HELIOS Klinikum, Klinik für Hämatologie, Onkologie und Immunologie
  Berlin, Germany Recruiting
• Charité Campus Benjamin Franklin, III. Med. Abt. (Hämatologie/Onkologie)
  Berlin, Germany Recruiting
• Klinikum Bielefeld, Klinik für Hämatologie, Onkologie und Palliativmedizin
  Bielefeld, Germany Recruiting
• Medizinische Universitätsklinik, Knappschaftskrankenhaus
  Bochum, Germany Recruiting
• Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik III, Schwerpunkt Onkologie, Hämatologie und Rheumatologie
  Bonn, Germany Recruiting
• Klinikum Chemnitz GmbH, Innere Medizin III
  Chemnitz, Germany Recruiting

Study contacts

• Principal investigator: Hartmut Goldschmidt, Prof. — University Hospital Heidelberg
• Study coordinator: Eileen Kurre
• Email: eileen.kurre@med.uni-heidelberg.de
• Phone: +49 6221 56-8246

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 6MW5311 in adults with relapsed or refractory blood cancers

  This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.

  Recruiting Phase 1 Mabwell (Shanghai) Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT07914556

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma

  In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.

  Recruiting Phase 4 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07907211

• Exercise phenotyping before chemotherapy in newly diagnosed multiple myeloma

  This observational study tests whether some newly diagnosed multiple myeloma patients with normal resting heart function already show limited exercise capacity, and whether that limitation relates to subtle heart tissue changes and future heart-related outcomes.

  Recruiting Technical University of Munich · Munich, Bavaria · NCT07851493

• SMS text check-ins to track symptoms for people with plasma cell disorders

  This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07850284

• Cevostamab with Pomalidomide and Dexamethasone after BCMA-directed CAR T therapy in multiple myeloma

  This study tests if Cevostamab combined with pomalidomide and dexamethasone can help people with multiple myeloma who have already had CAR T therapy and several prior treatments.

  Recruiting at 5 sites Phase 2 Hoffmann-La Roche · Nuremberg, Bavaria and 4 other locations · NCT07825064

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.